<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cell Rep</journal-id><journal-id journal-id-type="iso-abbrev">Cell Rep</journal-id><journal-title-group><journal-title>Cell Reports</journal-title></journal-title-group><issn pub-type="epub">2211-1247</issn><publisher><publisher-name>The Author(s).</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7332457</article-id><article-id pub-id-type="publisher-id">S2211-1247(20)30896-2</article-id><article-id pub-id-type="doi">10.1016/j.celrep.2020.107915</article-id><article-id pub-id-type="publisher-id">107915</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Potential Causes and Consequences of Gastrointestinal Disorders during a SARS-CoV-2 Infection</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Trottein</surname><given-names>Fran&#x000e7;ois</given-names></name><email>francois.trottein@pasteur-lille.fr</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Sokol</surname><given-names>Harry</given-names></name><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff4" ref-type="aff">4</xref></contrib><aff id="aff1"><label>1</label>Centre d&#x02019;Infection et d&#x02019;Immunit&#x000e9; de Lille, INSERM U1019, CNRS UMR 9017, University of Lille, CHU Lille-Institut Pasteur de Lille, 59000 Lille, France</aff><aff id="aff2"><label>2</label>Sorbonne Universit&#x000e9;, INSERM, Centre de Recherche Saint-Antoine, CRSA, AP-HP, Saint Antoine Hospital, Gastroenterology Department, 75012 Paris, France</aff><aff id="aff3"><label>3</label>INRA, UMR1319 Micalis &#x00026; AgroParisTech, 78350 Jouy en Josas, France</aff><aff id="aff4"><label>4</label>Paris Center for Microbiome Medicine, F&#x000e9;d&#x000e9;ration Hospitalo-Universitaire, 75012 Paris, France</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author <email>francois.trottein@pasteur-lille.fr</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>3</day><month>7</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><day>21</day><month>7</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>3</day><month>7</month><year>2020</year></pub-date><volume>32</volume><issue>3</issue><fpage>107915</fpage><lpage>107915</lpage><permissions><copyright-statement>&#x000a9; 2020 The Author(s)</copyright-statement><copyright-year>2020</copyright-year><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0010"><p>Coronaviruses cause several human diseases, including severe acute respiratory syndrome. The global coronavirus disease 2019 (COVID-19) pandemic has become a huge threat to humans. Intensive research on the pathogenic mechanisms used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is urgently needed&#x02014;notably to identify potential drug targets. Clinical studies of patients with COVID-19 have shown that gastrointestinal disorders appear to precede or follow the respiratory symptoms. Here, we review gastrointestinal disorders in patients with COVID-19, suggest hypothetical mechanisms leading to gut symptoms, and discuss the potential consequences of gastrointestinal disorders on the outcome of the disease. Lastly, we discuss the role of the gut microbiota during respiratory viral infections and suggest that targeting gut dysbiosis may help to control the pathogenesis of COVID-19.</p></abstract><abstract abstract-type="teaser" id="abs0015"><p>In this review, Trottein and Sokol present hypothetical mechanisms leading to gut symptoms in patients with COVID-19 and discuss their potential consequences on disease severity. They also discuss the role of the gut microbiota in disease and the potential interest of targeting it to improve COVID-19 pathogenesis.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>SARS-CoV-2</kwd><kwd>COVID-19</kwd><kwd>gastrointestinal symptoms</kwd><kwd>gut microbiota</kwd><kwd>microbial dysbiosis</kwd><kwd>disease outcomes</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>Main Text</title><p id="p0010">Coronaviruses are enveloped RNA viruses containing a large (25 to 32 kb), single-stranded, positive-sense RNA genome. These viruses circulate continuously in human populations and generally cause mild respiratory diseases, including the common cold. In contrast, the zoonotic severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) cause severe respiratory diseases and are associated with a high mortality rate when they spread to humans (<xref rid="bib15" ref-type="bibr">Fehr et&#x000a0;al., 2017</xref>). No specific antiviral drugs or vaccines have been approved for combating infections by SARS and MERS. In late 2019, a new infectious respiratory disease (now termed coronavirus disease 2019 [COVID-19]) emerged in Wuhan, China (<xref rid="bib55" ref-type="bibr">Wang et&#x000a0;al., 2020a</xref>; <xref rid="bib69" ref-type="bibr">Zhu et&#x000a0;al., 2020</xref>). This disease spread rapidly across China and to other countries. The World Health Organization recently declared the COVID-19 outbreak to be a pandemic. SARS-CoV-2 is the etiological agent of COVID-19 (<xref rid="bib69" ref-type="bibr">Zhu et&#x000a0;al., 2020</xref>). A phylogenetic analysis has shown that SARS-CoV-2 is most closely related to SARS-CoV (nucleotide similarity: 89.1%). COVID-19 is characterized by acute pathological outcomes, including pneumonia and acute respiratory distress syndrome (ARDS), and has a substantial mortality rate (<xref rid="bib9" ref-type="bibr">Chen et&#x000a0;al., 2020</xref>). ARDS during a SARS-CoV-2 infection is also associated with dysregulation of cytokine production, barrier leakage, and organ dysfunction. COVID-19 is more severe in individuals with comorbidities (diabetes mellitus, cardiovascular diseases, and hypertension) and in the elderly (<xref rid="bib20" ref-type="bibr">Guan et&#x000a0;al., 2020</xref>; <xref rid="bib58" ref-type="bibr">Wu and McGoogan, 2020</xref>).</p><sec id="sec1.1"><title>SARS-CoV-2 Can Target the Gastrointestinal Tract in Humans</title><p id="p0015">Both SARS-CoV and SARS-CoV-2 can infect host cells when the viral spike protein binds to its cell surface receptor angiotensin-converting enzyme II (ACE2). With the exception of human coronavirus (hCoV) NL63, the seven other hCoVs have other host cell receptors (also exopeptidases). ACE2 is a homolog of angiotensin-converting enzyme (ACE), the central enzyme in the renin-angiotensin-aldosterone system (RAAS), which is crucial for the physiology and pathology of all organs (<xref rid="bib16" ref-type="bibr">Gheblawi et&#x000a0;al., 2020</xref>). ACE2 maintains the homeostasis of RAAS as a negative regulator. Virus entry also requires cleavage of the spike protein (priming) by a type II transmembrane serine protease called TMPRSS2. This priming step is essential for fusion of the viral and cell membranes (<xref rid="bib37" ref-type="bibr">Matsuyama et&#x000a0;al., 2010</xref>; <xref rid="bib24" ref-type="bibr">Hoffmann et&#x000a0;al., 2020</xref>; <xref rid="bib66" ref-type="bibr">Zhou et&#x000a0;al., 2020a</xref>). Additional proteases (including furin) might be involved in SARS-CoV-2 priming (<xref rid="bib11" ref-type="bibr">Coutard et&#x000a0;al., 2020</xref>). SARS-CoV-2&#x02019;s binding affinity for human ACE2 is 10 to 20 times greater than that of SARS-CoV; this disparity might result from differences in spike protein methylation and/or cleavage sites (<xref rid="bib28" ref-type="bibr">Jin et&#x000a0;al., 2020</xref>; <xref rid="bib56" ref-type="bibr">Wang et&#x000a0;al., 2020b</xref>). Hence, the expression of ACE2 is essential for SARS-CoV-2&#x02019;s entry into host cells. As discussed later, changes in ACE2&#x02019;s functional activity might critically affect the disease outcome. In humans, ACE2 and TMPRSS2 are strongly expressed in lung tissue in general and by epithelial cells in particular. This strong expression explains why the lung appears to be the most vulnerable target organ during COVID-19. A recent single-cell analysis revealed that more than 80% of ACE2-expressing pulmonary cells were type II alveolar cells (<xref rid="bib65" ref-type="bibr">Zhao et&#x000a0;al., 2020</xref>); hence, this cell type might have a crucial role in coronavirus invasion and replication. Bronchial transient secretory cells (with a phenotype between those of goblet cells and ciliated cells) also express high levels of ACE2 (<xref rid="bib35" ref-type="bibr">Lukassen et&#x000a0;al., 2020</xref>). Furthermore, epithelial cells in the upper respiratory tract (specifically nasal goblet/secretory cells and ciliated cells) express both ACE2 and TMPRSS2 (<xref rid="bib52" ref-type="bibr">Sungnak et&#x000a0;al., 2020</xref>). This combined expression in the upper airways may be correlated with enhanced transmission of the virus. ACE2 is also expressed in many extrapulmonary tissues, including the heart, liver, kidney, and intestine (<xref rid="bib12" ref-type="bibr">Crackower et&#x000a0;al., 2002</xref>; <xref rid="bib21" ref-type="bibr">Hamming et&#x000a0;al., 2004</xref>; <xref rid="bib22" ref-type="bibr">Hashimoto et&#x000a0;al., 2012</xref>). In the latter, high levels of ACE2 are found on the luminal surface of differentiated epithelial cells in the small intestine, whereas levels are lower in the crypt cells and in the colon (<xref rid="bib22" ref-type="bibr">Hashimoto et&#x000a0;al., 2012</xref>; <xref rid="bib33" ref-type="bibr">Liang et&#x000a0;al., 2020</xref>). Human proximal and distal enterocytes coexpress dipeptidyl peptidase-4 (the receptor for MERS-CoV) and alanine aminopeptidase (the receptor for hCoV-229E) (<xref rid="bib33" ref-type="bibr">Liang et&#x000a0;al., 2020</xref>). In the intestine, ACE2 acts as a coreceptor for nutrient uptake and especially amino acid absorption from food (<xref rid="bib22" ref-type="bibr">Hashimoto et&#x000a0;al., 2012</xref>). On the one hand, the gut might be a major entry site for SARS-CoV-2; this would suggest that consumption of contaminated food can propagate the virus in humans. On the other hand, the intestinal expression of ACE2 might have essential implications for fecal-oral transmission and thus the containment of viral spreading. As seen during previous coronavirus outbreaks, around half of all COVID-19 patients have detectable SARS-CoV-2 RNA in their stools&#x02014;even when it is no longer found in the respiratory tract (<xref rid="bib64" ref-type="bibr">Zhang et&#x000a0;al., 2020</xref>; <xref rid="bib60" ref-type="bibr">Xiao et&#x000a0;al., 2020b</xref>; <xref rid="bib57" ref-type="bibr">Wang et&#x000a0;al., 2020c</xref>). The virus has also been detected in gastrointestinal histological samples and by endoscopy (<xref rid="bib59" ref-type="bibr">Xiao et&#x000a0;al., 2020a</xref>; <xref rid="bib34" ref-type="bibr">Lin et&#x000a0;al., 2020</xref>). Importantly, infectious viruses were detected in fecal samples of COVID-19 patients, suggesting that the digestive tract might be a site of viral replication and activity (<xref rid="bib60" ref-type="bibr">Xiao et&#x000a0;al., 2020b</xref>; <xref rid="bib68" ref-type="bibr">Zhou et&#x000a0;al., 2020c</xref>). Several studies using human small intestinal organoids have shown that SARS-CoV-2 replicates in enterocytes (<xref rid="bib68" ref-type="bibr">Zhou et&#x000a0;al., 2020c</xref>; <xref rid="bib63" ref-type="bibr">Zang et&#x000a0;al., 2020</xref>; <xref rid="bib31" ref-type="bibr">Lamers et&#x000a0;al., 2020</xref>). The presence of virus in the stools and its fecal persistence suggest that fecal-oral transmission is possible. A study (mouse system) reported that intragastric inoculation of SARS-CoV-2 causes productive infection and leads to pulmonary pathological changes (<xref rid="bib51" ref-type="bibr">Sun et&#x000a0;al., 2020</xref>). Collectively, the lung is not the only site targeted by SARS-CoV-2, and enteric infection occurs. Here, we review gastrointestinal disorders in patients with COVID-19, suggest hypothetical mechanisms leading to gut symptoms, and discuss the potential consequences of gastrointestinal disorders on the outcome of the disease.</p></sec><sec id="sec1.2"><title>SARS-CoV-2 Causes Gastrointestinal Disorders in Humans</title><p id="p0020">Various research groups have analyzed the epidemiological and clinical characteristics of gastrointestinal disorders in patients with COVID-19. The percentage of patients with gastrointestinal disorders (as evidenced by vomiting, nausea, and/or diarrhea) varies depending on the study. In China, Jin and colleagues enrolled 651 patients on admission, i.e., before treatment with antiviral or antibiotic drugs, which might have biased the analysis (<xref rid="bib28" ref-type="bibr">Jin et&#x000a0;al., 2020</xref>). Interestingly, 11.4% of COVID-19 patients had at least one gastrointestinal tract symptom, the most common being diarrhea (in 5% to 8% of patients). In the study by Jin and colleagues, the intestinal disorders lasted a median of 4&#x000a0;days and appeared to precede the respiratory symptoms. Gastrointestinal symptoms were more frequent in severe/critical cases of COVID-19 (23%) than in mild COVID-19 (8%) (<xref rid="bib28" ref-type="bibr">Jin et&#x000a0;al., 2020</xref>). In other studies performed in China and Hong Kong, the proportion of COVID-19 patients (n total&#x000a0;= 254, 59, 204, 58, 138, and 1,099, respectively) who developed gastrointestinal disorders was 26%, 25.4%, 18.6%, 11%, 13.7%, and 8.7%, respectively (<xref rid="bib67" ref-type="bibr">Zhou et&#x000a0;al., 2020b</xref>; <xref rid="bib10" ref-type="bibr">Cheung et&#x000a0;al., 2020</xref>; <xref rid="bib40" ref-type="bibr">Pan et&#x000a0;al., 2020</xref>; <xref rid="bib34" ref-type="bibr">Lin et&#x000a0;al., 2020</xref>; <xref rid="bib57" ref-type="bibr">Wang et&#x000a0;al., 2020c</xref>, <xref rid="bib20" ref-type="bibr">Guan et&#x000a0;al., 2020</xref>). Other studies (of 40 COVID-19 patients in Europe and 278 and 318 COVID-19 patients in the United States) reported that 55%, 35%, and 61% of the patients, respectively, displayed gastrointestinal signs and symptoms (<xref rid="bib14" ref-type="bibr">Effenberger et&#x000a0;al., 2020</xref>; <xref rid="bib39" ref-type="bibr">Nobel et&#x000a0;al., 2020</xref>; <xref rid="bib44" ref-type="bibr">Redd et&#x000a0;al., 2020</xref>). Importantly, meta-analyses of studies totaling 4,243, 6,686, and 10,890 patients found that the pooled prevalence of gastrointestinal symptoms was 17.6%, 15%, and 10%, respectively (<xref rid="bib10" ref-type="bibr">Cheung et&#x000a0;al., 2020</xref>; <xref rid="bib36" ref-type="bibr">Mao et&#x000a0;al., 2020</xref>; <xref rid="bib50" ref-type="bibr">Sultan et&#x000a0;al., 2020</xref>). SARS-CoV-2 infection triggers an inflammatory response in the gut, as evidenced by elevated fecal levels of calprotectin (a marker protein expressed mainly by neutrophils) (<xref rid="bib14" ref-type="bibr">Effenberger et&#x000a0;al., 2020</xref>). Lin and colleagues also observed that although the presence of SARS-CoV-2 in the stool does not correlate with gastrointestinal symptoms, the presence of SARS-CoV-2 in intestinal tissue is generally associated with severe gastrointestinal symptoms (<xref rid="bib34" ref-type="bibr">Lin et&#x000a0;al., 2020</xref>). The use of human small intestinal organoids will be instrumental in better analyzing the modalities of enterocyte infection and its impact on the inflammatory response. Furthermore, it will be interesting in the future to determine the consequences of pre-existing digestive diseases (i.e., inflammatory bowel disease) on gastrointestinal disorders caused by SARS-CoV-2 and on the severity of COVID-19.</p></sec><sec id="sec1.3"><title>Potential Mechanisms of Gastrointestinal Disorders in COVID-19</title><p id="p0025">Gastrointestinal disorders in COVID-19 patients are likely to have several etiological factors. The recruitment of inflammatory cells (i.e., from the bone marrow) and/or the systemic and local production of inflammatory cytokines are likely to have a role. In this setting, local inflammation might weaken the epithelial barrier. Cellular damage induced directly by viral replication and spreading might also actively contribute to injury and inflammation of the gut epithelium. Gastrointestinal symptoms in COVID-19 patients might also result from dysfunction of ACE2. As mentioned earlier, ACE2 is a key regulatory enzyme in the RAAS, and the latter is known to influence immune functions and inflammation (<xref rid="bib43" ref-type="bibr">Ranjbar et&#x000a0;al., 2019</xref>). ACE2 is an essential regulator of intestinal homeostasis, and a lack of this enzyme accentuates the intestine&#x02019;s susceptibility to inflammation (<xref rid="bib22" ref-type="bibr">Hashimoto et&#x000a0;al., 2012</xref>). The intestinal phenotype is (at least partly) due to ACE2&#x02019;s non-catalytic function. A lack of ACE2 alters the expression of the neutral amino acid transporter B<sup>0</sup>AT1 on intestinal epithelial cells, which lowers the intake of tryptophan and thus reduces the production of nicotinamide and (potentially) other tryptophan-derived metabolites with a critical role in intestinal homeostasis (<xref rid="bib22" ref-type="bibr">Hashimoto et&#x000a0;al., 2012</xref>; <xref rid="bib2" ref-type="bibr">Agus et&#x000a0;al., 2018</xref>). Binding of the viral spike protein to ACE2 leads to reduced expression of the latter but does not change the expression of ACE (<xref rid="bib30" ref-type="bibr">Kuba et&#x000a0;al., 2005</xref>). During SARS-CoV infections, the expression of ACE2 is considerably reduced&#x02014;at least in the lungs (<xref rid="bib30" ref-type="bibr">Kuba et&#x000a0;al., 2005</xref>). Given the key role of ACE2 in intestinal homeostasis, reduced expression and impaired function of this protein during a SARS-CoV infection might substantially contribute to local disorders and pathogenesis. It remains to be seen whether drugs able to modulate ACE2 expression, such as ACE inhibitors or angiotensin II receptor blockers (used in hypertension and diabetes), can modulate gastrointestinal disorders, including gut dysbiosis, in the context of SARS-CoV-2 infection. Along with inflammation and dysfunction of ACE2, other mechanisms might be implicated in gastrointestinal symptoms in COVID-19 patients. Because hypoxia is a major clinical symptom in COVID-19 patients (<xref rid="bib8" ref-type="bibr">Cavezzi et&#x000a0;al., 2020</xref>) and is known to be critical in intestinal homeostasis, including microbiota composition and function (<xref rid="bib48" ref-type="bibr">Singhal and Shah., 2020</xref>), it is also likely that oxygen deprivation might be important in gastrointestinal disorders and disease severity. Recent evidence suggests that SARS-CoV-2 may affect the central nervous system (<xref rid="bib41" ref-type="bibr">Paniz-Mondolfi et&#x000a0;al., 2020</xref>; <xref rid="bib23" ref-type="bibr">Helms et&#x000a0;al., 2020</xref>). Regarding the importance of the gut-brain axis, one can speculate that this may play a role in gastrointestinal disorders during SARS-CoV-2 infection. It is possible that the enteric nervous system could be affected by SARS-CoV-2, either by direct viral infection or through the elicited immune response (e.g., inflammatory cytokines), amplifying diarrhea and possibly stimulating the vagus nerve to promote vomiting.</p></sec><sec id="sec1.4"><title>ACE2 Dysfunction Alters the Composition of the Gut Microbiota</title><p id="p0030">It is well established that the gut microbiota has a critical role in intestinal homeostasis and that changes in its composition and function activity are involved in local inflammation (<xref rid="bib5" ref-type="bibr">Blander et&#x000a0;al., 2017</xref>; <xref rid="bib32" ref-type="bibr">Lavelle and Sokol, 2020</xref>). A lack of ACE2 leads to substantial alteration in the composition of the gut microbiota in mice; this partly results from reduced production of the antimicrobial peptides that control the gut&#x02019;s microbial community (<xref rid="bib22" ref-type="bibr">Hashimoto et&#x000a0;al., 2012</xref>). Moreover, disruption of the ACE/ACE2 axis during pulmonary hypertension (loss of ACE2) is associated with alteration of the gut microbiota in humans (<xref rid="bib45" ref-type="bibr">Santisteban et&#x000a0;al., 2016</xref>; <xref rid="bib29" ref-type="bibr">Kim et&#x000a0;al., 2020</xref>). One can speculate that the decrease in ACE2 availability during SARS-COV-2 infection is enough to alter the composition of the gut microbiota. Recent pilot studies suggest gut microbiota alterations during SARS-CoV-2 infection (<xref rid="bib62" ref-type="bibr">Yu et&#x000a0;al., 2020</xref>; <xref rid="bib19" ref-type="bibr">Gu et&#x000a0;al., 2020b</xref>; <xref rid="bib70" ref-type="bibr">Zuo et&#x000a0;al., 2020</xref>). In a cohort of 30 COVID-19 patients (fecal sample analysis using 16S rRNA gene sequencing), infection was associated with a significant decrease of bacterial diversity and abundance (<xref rid="bib19" ref-type="bibr">Gu et&#x000a0;al., 2020b</xref>). Significant changes in gut microbial communities were noticed, including lower relative abundance of beneficial (butyrate-producing) bacteria, such as several genera from the <italic>Ruminococcaceae</italic> and <italic>Lachnospiraceae</italic> families. However, significantly higher relative abundance occurred of opportunistic pathogens, including <italic>Streptococcus</italic>, <italic>Rothia</italic>, <italic>Veillonella</italic>, and <italic>Actinomyces</italic>. Of interest, the gut microbial signature of patients with COVID-19 was different from that of H1N1 patients (<xref rid="bib19" ref-type="bibr">Gu&#x000a0;et&#x000a0;al., 2020b</xref>). Enrichment of opportunistic pathogens and depletion of beneficial commensals was also observed in a (longitudinal) study using deep shotgun metagenomics (15 COVID-19 patients) (<xref rid="bib70" ref-type="bibr">Zuo et&#x000a0;al., 2020</xref>). In particular, enrichment of opportunistic pathogens known to cause bacteremia, including <italic>Clostridium hathewayi</italic>, <italic>Actinomyces viscosus</italic>, and <italic>Bacteroides nordii</italic>, was observed. Lower relative abundance of beneficial commensals, including the anti-inflammatory bacterium <italic>Faecalibacterium prausnitzii</italic>, <italic>Alistipes onderdonkii</italic>, <italic>Roseburia</italic>, and <italic>Lachnospiraceae taxa</italic>, was also noticed. The authors found a correlation between rise or drop of these bacteria and disease severity. Of note, altered microbiota composition persisted after clearance of SARS-CoV-2 and resolution of respiratory symptoms, indicating that resiliency is long lasting (<xref rid="bib70" ref-type="bibr">Zuo et&#x000a0;al., 2020</xref>). Hence, SARS-CoV-2 infection modifies the composition of the gut microbiota in humans. It is possible that reduced levels of commensal bacteria with important physiological functions, such as butyrate producers, may promote the overgrowth of intestinal conditional pathogenic bacteria. Whether these changes increase intestinal mucosal permeability and endotoxin concentrations in the blood, ultimately triggering inflammation and cytokine release exacerbation, remains to be investigated (<xref rid="fig1" ref-type="fig">Figure 1</xref>
). Further analyses are urgently needed in larger human cohorts to confirm and detail gut microbiota alterations in COVID-19 patients. Studies should prospectively include asymptomatic COVID-19-confirmed subjects and patients at disease onset, during disease course, and over the long term after discovery to delineate the role of microbiome changes in SARS-CoV-2 infection and post-infection recovery. It will be critical to consider patients treated or not with antibiotics (and other medications) and the comorbidity status of those patients. The consequences of SARS-CoV-2 infection on the gut microbiota should also be investigated in relevant animal models of COVID-19. Possible models include non-human primates, ferrets, human-ACE2-expressing mice, and hamsters (<xref rid="bib7" ref-type="bibr">Callaway, 2020</xref>). The impact of SARS-CoV-2 on the gut microbiota&#x02019;s metabolic output also remains to be defined. This aspect is of particular importance because in a mouse model, the altered gut microbiota associated with ACE2 deficiency (1) favors intestinal inflammation and (2) confers susceptibility to colitis when transferred to wild-type animals (<xref rid="bib22" ref-type="bibr">Hashimoto et&#x000a0;al., 2012</xref>). In parallel, it remains to be determined whether alterations in the microbiota influence the extraintestinal outcomes of COVID-19. Altogether, direct enterocyte infection, disruption of the enteric ACE2 axis (and interference with nutrient absorption), hypoxia, alterations of the enteric nervous system and local immune response, and changes in inflammatory cytokine levels might lead to adverse intestinal outcomes (including dysbiosis) in patients with COVID-19.<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>The Gut Microbiota&#x02019;s Hypothetical Role in SARS-CoV-2 Infection</p><p>A healthy gut microbiota boosts the lungs&#x02019; antiviral response, including interferon production and the effector function of CD8<sup>+</sup> T&#x000a0;cells (step 1). Soon after infection, SARS-CoV-2 replicates in the intestinal compartment and decreases the expression and activity of ACE2 (step 2). This leads to gut dysbiosis and gastrointestinal symptoms (step 3). Meanwhile, viral infection of the lungs triggers the systemic production of interferons and elicits weight loss, both of which trigger gut dysbiosis (step 3). Changes in the composition and functional activity of the gut microbiota and impairment of the gut&#x02019;s barrier function contribute to disease outcomes, including ARDS, a systemic cytokine storm, and multiorgan dysfunction (step 4).</p></caption><graphic xlink:href="gr1_lrg"/></fig></p></sec><sec id="sec1.5"><title>The Potential Role of the Gut Microbiota in COVID-19 Outcomes</title><p id="p0035">Evidence suggests that the gut microbiota can remotely boost the host&#x02019;s response to respiratory viral infections. Paradoxically, dysbiosis of the microbiota can also worsen the outcome of the disease. The gut microbiota&#x02019;s role in hCoV infections has yet to be defined. In the setting of influenza infections, the results of experiments with antibiotic treatment (to deplete the residual microbiota) have demonstrated that the gut microbiota is critical for controlling viral replication (<xref rid="bib27" ref-type="bibr">Ichinohe et&#x000a0;al., 2011</xref>; <xref rid="bib1" ref-type="bibr">Abt et&#x000a0;al., 2012</xref>; <xref rid="bib49" ref-type="bibr">Steed et&#x000a0;al., 2017</xref>; <xref rid="bib6" ref-type="bibr">Bradley et&#x000a0;al., 2019</xref>). Bacterial cell wall components and bacterial metabolites (such as desaminotyrosine) favor the production of type I interferons and inflammasome-dependent cytokines by pulmonary cells. The gut microbiota also boosts CD8<sup>+</sup> T&#x000a0;cell effector function, a process that contributes to viral clearance (<xref rid="bib27" ref-type="bibr">Ichinohe et&#x000a0;al., 2011</xref>). Whereas altering the gut microbiota with antibiotics increases the severity of the infection, stimulating the microbiome with a high-fiber diet has the opposite effect (<xref rid="bib53" ref-type="bibr">Trompette et&#x000a0;al., 2018</xref>). The stimulatory mechanisms involve short-chain fatty acids (SCFAs, the end products of dietary fiber fermentation by commensal bacteria) that are absorbed by and act on immune cells to reduce the inflammatory component of infection. SCFAs also enhance the effector activity of CD8<sup>+</sup> T&#x000a0;cells by stimulating cellular metabolism (<xref rid="bib53" ref-type="bibr">Trompette et&#x000a0;al., 2018</xref>). Similar protective effects have been observed with the respiratory syncytial virus (<xref rid="bib3" ref-type="bibr">Antunes et&#x000a0;al., 2019</xref>). It remains to be seen whether the gut microbiota also participates in early control (through innate immunity) and late control (through adaptive immunity) of coronavirus replication, and this topic warrants investigation (<xref rid="fig1" ref-type="fig">Figure 1</xref>). It would also be useful to investigate the effect of SCFA-promoting high-fiber diets and/or probiotics on the outcome of SARS-CoV-2 infection.</p><p id="p0040">Patients with respiratory infections generally have gut-dysfunction-related complications that worsen the clinical course. For example, this type of gut-lung crosstalk has been described during influenza infections in both humans and animal models. Severe influenza A virus infection is associated with intestinal disorders and gut microbiota alterations (<xref rid="bib54" ref-type="bibr">Wang et&#x000a0;al., 2014</xref>; <xref rid="bib42" ref-type="bibr">Qin et&#x000a0;al., 2015</xref>; <xref rid="bib13" ref-type="bibr">Deriu et&#x000a0;al., 2016</xref>; <xref rid="bib17" ref-type="bibr">Groves et&#x000a0;al., 2018</xref>; <xref rid="bib61" ref-type="bibr">Yildiz et&#x000a0;al., 2018</xref>; <xref rid="bib46" ref-type="bibr">Sencio et&#x000a0;al., 2020</xref>). These changes were attributed partly to infection-related reduction in food consumption (<xref rid="bib46" ref-type="bibr">Sencio et&#x000a0;al., 2020</xref>) and to interferon production (<xref rid="bib54" ref-type="bibr">Wang et&#x000a0;al., 2014</xref>; <xref rid="bib13" ref-type="bibr">Deriu et&#x000a0;al., 2016</xref>). We recently looked at whether microbiota conditioned by influenza A virus enhanced susceptibility to bacterial superinfection, a major cause of mortality during epidemics and pandemics (<xref rid="bib38" ref-type="bibr">McCullers, 2014</xref>). In fecal transfer experiments, we showed that the dysbiotic microbiota remotely compromises the lung&#x02019;s defenses against pneumococcal infection. In mechanistic terms, a reduction in SCFA production is associated with a decrease in the alveolar macrophages&#x02019; bactericidal activity (<xref rid="bib46" ref-type="bibr">Sencio et&#x000a0;al., 2020</xref>).</p><p id="p0045">Whether gut disorders (including microbiota alterations) influence on outcomes in COVID-19 is still an open question. Evidence suggests that SARS-CoV-2 infection alters the gut-blood barrier and thus leads to systemic dissemination of bacteria, endotoxins, and microbial metabolites (<xref rid="bib57" ref-type="bibr">Wang et&#x000a0;al., 2020c</xref>; <xref rid="bib26" ref-type="bibr">Huang et&#x000a0;al., 2020</xref>; <xref rid="bib20" ref-type="bibr">Guan et&#x000a0;al., 2020</xref>). This might affect the host&#x02019;s initial response to SARS-CoV-2 infection and might then contribute to multisystem dysfunction, septic shock, and the systemic inflammation storm seen in the second phase of SARS-CoV-2 infection, which typically result in death (<xref rid="bib20" ref-type="bibr">Guan et&#x000a0;al., 2020</xref>; <xref rid="bib26" ref-type="bibr">Huang et&#x000a0;al., 2020</xref>; <xref rid="bib57" ref-type="bibr">Wang et&#x000a0;al., 2020c</xref>). Clinical studies have demonstrated that the presence of a gastrointestinal disorder in COVID-19 patients is associated with a more aggressive clinical course, including ARDS, liver injury, a higher body temperature, and shock (<xref rid="bib28" ref-type="bibr">Jin et&#x000a0;al., 2020</xref>). Moreover, the risk factors for severity and mortality in COVID-19 (such as diabetes) (<xref rid="bib47" ref-type="bibr">Singh et&#x000a0;al., 2020</xref>) are known to be associated with disturbances of the intestinal microbiota and, in particular, low production of SCFAs. This is particularly the case for patients with metabolic syndrome (obesity, high blood pressure, and diabetes) who exhibit severity factors for viral infections (including respiratory infections) (<xref rid="bib4" ref-type="bibr">Badawi et&#x000a0;al., 2018</xref>; <xref rid="bib25" ref-type="bibr">Honce and Schultz-Cherry, 2019</xref>). The role of intestinal dysbiosis in this setting needs to be investigated, e.g., by performing fecal transfer experiments in relevant animal models. We speculate that ACE2 disruption, changes in microbial profiles, and intestinal inflammation and leakiness during SARS-CoV infection strongly amplify systemic pathways in comorbid individuals and exacerbate underlying pathologies (e.g., diabetes and hypertension). SARS-CoV-2 infection may also deteriorate the course of human inflammatory bowel diseases (<xref rid="bib14" ref-type="bibr">Effenberger et&#x000a0;al., 2020</xref>). The mortality rate associated with SARS-CoV-2 infection is higher in older adults, who also tend to display chronic low-grade inflammation with underlying microbiota alterations and gut leakiness. In the setting of COVID-19, can we exploit the gut microbiota for the patient&#x02019;s benefit? At present, no direct clinical evidence suggests that modulation of the gut microbiota has therapeutic value in patients with COVID-19. However, it is tempting to speculate that targeting gut microbiota might be a therapeutic option.</p></sec><sec id="sec1.6"><title>Concluding Remarks</title><p id="p0050">The complex pathogenesis of SARS-CoV-2 infection is only starting to be deciphered. Along with the respiratory tract, the gastrointestinal tract is an entry and replication site for SARS-CoV-2. The gut constitutes one of the main extrapulmonary target organs with regard to symptoms and is a potential route for virus dissemination; its role therefore needs to be actively explored. In particular, several lines of evidence suggest that SARS-CoV-2 infection is associated with alteration of the gut microbiota. It remains to be determined whether the gut microbiota influences the gastrointestinal and pulmonary signs and symptoms of COVID-19 and overall mortality. Putative changes in the gut microbiota&#x02019;s composition and functional activity might be biomarkers of disease severity. Lastly, and if the gut microbiota does prove to affect the disease&#x02019;s severity and mortality rate, targeting the microbiota&#x02019;s various components might be an attractive therapeutic strategy. In this setting, conventional approaches like antibiotic treatment targeting pathobionts (preferably with a narrow-spectrum drug), probiotics, and fecal transfer might be relevant. However, more specific interventions (e.g., live biotherapies or microbiota-derived metabolites) based on an in-depth understanding of the mechanisms involved are attractive.</p></sec></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Abt</surname><given-names>M.C.</given-names></name><name><surname>Osborne</surname><given-names>L.C.</given-names></name><name><surname>Monticelli</surname><given-names>L.A.</given-names></name><name><surname>Doering</surname><given-names>T.A.</given-names></name><name><surname>Alenghat</surname><given-names>T.</given-names></name><name><surname>Sonnenberg</surname><given-names>G.F.</given-names></name><name><surname>Paley</surname><given-names>M.A.</given-names></name><name><surname>Antenus</surname><given-names>M.</given-names></name><name><surname>Williams</surname><given-names>K.L.</given-names></name><name><surname>Erikson</surname><given-names>J.</given-names></name></person-group><article-title>Commensal bacteria calibrate the activation threshold of innate antiviral immunity</article-title><source>Immunity</source><volume>37</volume><year>2012</year><fpage>158</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">22705104</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Agus</surname><given-names>A.</given-names></name><name><surname>Planchais</surname><given-names>J.</given-names></name><name><surname>Sokol</surname><given-names>H.</given-names></name></person-group><article-title>Gut microbiota regulation of tryptophan metabolism in health and disease</article-title><source>Cell Host Microbe</source><volume>23</volume><year>2018</year><fpage>716</fpage><lpage>724</lpage><pub-id pub-id-type="pmid">29902437</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Antunes</surname><given-names>K.H.</given-names></name><name><surname>Fachi</surname><given-names>J.L.</given-names></name><name><surname>de Paula</surname><given-names>R.</given-names></name><name><surname>da Silva</surname><given-names>E.F.</given-names></name><name><surname>Pral</surname><given-names>L.P.</given-names></name><name><surname>Dos Santos</surname><given-names>A.&#x000c1;.</given-names></name><name><surname>Dias</surname><given-names>G.B.M.</given-names></name><name><surname>Vargas</surname><given-names>J.E.</given-names></name><name><surname>Puga</surname><given-names>R.</given-names></name><name><surname>Mayer</surname><given-names>F.Q.</given-names></name></person-group><article-title>Microbiota-derived acetate protects against respiratory syncytial virus infection through a GPR43-type 1 interferon response</article-title><source>Nat. Commun.</source><volume>10</volume><year>2019</year><fpage>3273</fpage><lpage>3289</lpage><pub-id pub-id-type="pmid">31332169</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Badawi</surname><given-names>A.</given-names></name><name><surname>Velummailum</surname><given-names>R.</given-names></name><name><surname>Ryoo</surname><given-names>S.G.</given-names></name><name><surname>Senthinathan</surname><given-names>A.</given-names></name><name><surname>Yaghoubi</surname><given-names>S.</given-names></name><name><surname>Vasileva</surname><given-names>D.</given-names></name><name><surname>Ostermeier</surname><given-names>E.</given-names></name><name><surname>Plishka</surname><given-names>M.</given-names></name><name><surname>Soosaipillai</surname><given-names>M.</given-names></name><name><surname>Arora</surname><given-names>P.</given-names></name></person-group><article-title>Prevalence of chronic comorbidities in dengue fever and West Nile virus: A systematic review and meta-analysis</article-title><source>PLoS ONE</source><volume>13</volume><year>2018</year><fpage>e0200200</fpage><pub-id pub-id-type="pmid">29990356</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Blander</surname><given-names>J.M.</given-names></name><name><surname>Longman</surname><given-names>R.S.</given-names></name><name><surname>Iliev</surname><given-names>I.D.</given-names></name><name><surname>Sonnenberg</surname><given-names>G.F.</given-names></name><name><surname>Artis</surname><given-names>D.</given-names></name></person-group><article-title>Regulation of inflammation by microbiota interactions with the host</article-title><source>Nat. Immunol.</source><volume>18</volume><year>2017</year><fpage>851</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">28722709</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Bradley</surname><given-names>K.C.</given-names></name><name><surname>Finsterbusch</surname><given-names>K.</given-names></name><name><surname>Schnepf</surname><given-names>D.</given-names></name><name><surname>Crotta</surname><given-names>S.</given-names></name><name><surname>Llorian</surname><given-names>M.</given-names></name><name><surname>Davidson</surname><given-names>S.</given-names></name><name><surname>Fuchs</surname><given-names>S.Y.</given-names></name><name><surname>Staeheli</surname><given-names>P.</given-names></name><name><surname>Wack</surname><given-names>A.</given-names></name></person-group><article-title>Microbiota-driven tonic interferon signals in lung stromal cells protect from influenza virus infection</article-title><source>Cell Rep.</source><volume>28</volume><year>2019</year><fpage>245</fpage><lpage>256.e4</lpage><pub-id pub-id-type="pmid">31269444</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Callaway</surname><given-names>E.</given-names></name></person-group><article-title>Labs rush to study coronavirus in transgenic animals&#x02014;some are in short supply</article-title><source>Nature</source><volume>579</volume><year>2020</year><fpage>183</fpage></element-citation></ref><ref id="bib8"><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Cavezzi</surname><given-names>A.</given-names></name><name><surname>Troiani</surname><given-names>E.</given-names></name><name><surname>Corrao</surname><given-names>S.</given-names></name></person-group><article-title>COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review</article-title><source>Clin. Pract.</source><volume>10</volume><year>2020</year><fpage>1271</fpage><lpage>1277</lpage><pub-id pub-id-type="pmid">32509258</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>D.</given-names></name><name><surname>Guo</surname><given-names>W.</given-names></name><name><surname>Cao</surname><given-names>Y.</given-names></name><name><surname>Huang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Yu</surname><given-names>H.</given-names></name></person-group><article-title>Clinical and immunological features of severe and moderate coronavirus disease 2019</article-title><source>J.&#x000a0;Clin. Invest.</source><volume>130</volume><year>2020</year><fpage>2620</fpage><lpage>2629</lpage><pub-id pub-id-type="pmid">32217835</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>K.S.</given-names></name><name><surname>Hung</surname><given-names>I.F.N.</given-names></name><name><surname>Chan</surname><given-names>P.P.Y.</given-names></name><name><surname>Lung</surname><given-names>K.C.</given-names></name><name><surname>Tso</surname><given-names>E.</given-names></name><name><surname>Liu</surname><given-names>R.</given-names></name><name><surname>Ng</surname><given-names>Y.Y.</given-names></name><name><surname>Chu</surname><given-names>M.Y.</given-names></name><name><surname>Chung</surname><given-names>T.W.H.</given-names></name><name><surname>Tam</surname><given-names>A.R.</given-names></name></person-group><article-title>Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis</article-title><source>Gastroenterology</source><year>2020</year><pub-id pub-id-type="doi">10.1053/j.gastro.2020.03.065</pub-id><comment>Published online April 3, 2020</comment></element-citation></ref><ref id="bib11"><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Coutard</surname><given-names>B.</given-names></name><name><surname>Valle</surname><given-names>C.</given-names></name><name><surname>de Lamballerie</surname><given-names>X.</given-names></name><name><surname>Canard</surname><given-names>B.</given-names></name><name><surname>Seidah</surname><given-names>N.G.</given-names></name><name><surname>Decroly</surname><given-names>E.</given-names></name></person-group><article-title>The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade</article-title><source>Antiviral Res.</source><volume>176</volume><year>2020</year><fpage>104742</fpage><lpage>104746</lpage><pub-id pub-id-type="pmid">32057769</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Crackower</surname><given-names>M.A.</given-names></name><name><surname>Sarao</surname><given-names>R.</given-names></name><name><surname>Oudit</surname><given-names>G.Y.</given-names></name><name><surname>Yagil</surname><given-names>C.</given-names></name><name><surname>Kozieradzki</surname><given-names>I.</given-names></name><name><surname>Scanga</surname><given-names>S.E.</given-names></name><name><surname>Oliveira-dos-Santos</surname><given-names>A.J.</given-names></name><name><surname>da Costa</surname><given-names>J.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Pei</surname><given-names>Y.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 is an essential regulator of heart function</article-title><source>Nature</source><volume>417</volume><year>2002</year><fpage>822</fpage><lpage>828</lpage><pub-id pub-id-type="pmid">12075344</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Deriu</surname><given-names>E.</given-names></name><name><surname>Boxx</surname><given-names>G.M.</given-names></name><name><surname>He</surname><given-names>X.</given-names></name><name><surname>Pan</surname><given-names>C.</given-names></name><name><surname>Benavidez</surname><given-names>S.D.</given-names></name><name><surname>Cen</surname><given-names>L.</given-names></name><name><surname>Rozengurt</surname><given-names>N.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Cheng</surname><given-names>G.</given-names></name></person-group><article-title>Influenza virus affects intestinal microbiota and secondary Salmonella infection in the gut through type I interferons</article-title><source>PLoS Pathog.</source><volume>12</volume><year>2016</year><fpage>e1005572</fpage><pub-id pub-id-type="pmid">27149619</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Effenberger</surname><given-names>M.</given-names></name><name><surname>Grabherr</surname><given-names>F.</given-names></name><name><surname>Mayr</surname><given-names>L.</given-names></name><name><surname>Schwaerzler</surname><given-names>J.</given-names></name><name><surname>Nairz</surname><given-names>M.</given-names></name><name><surname>Seifert</surname><given-names>M.</given-names></name><name><surname>Hilbe</surname><given-names>R.</given-names></name><name><surname>Seiwald</surname><given-names>S.</given-names></name><name><surname>Scholl-Buergi</surname><given-names>S.</given-names></name><name><surname>Fritsche</surname><given-names>G.</given-names></name></person-group><article-title>Faecal calprotectin indicates intestinal inflammation in COVID-19</article-title><source>Gut</source><year>2020</year><pub-id pub-id-type="doi">10.1136/gutjnl-2020-321388</pub-id><comment>Published online April 20, 2020</comment></element-citation></ref><ref id="bib15"><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Fehr</surname><given-names>A.R.</given-names></name><name><surname>Channappanavar</surname><given-names>R.</given-names></name><name><surname>Perlman</surname><given-names>S.</given-names></name></person-group><article-title>Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus</article-title><source>Annu. Rev. Med.</source><volume>68</volume><year>2017</year><fpage>387</fpage><lpage>399</lpage><pub-id pub-id-type="pmid">27576010</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Gheblawi</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>K.</given-names></name><name><surname>Viveiros</surname><given-names>A.</given-names></name><name><surname>Nguyen</surname><given-names>Q.</given-names></name><name><surname>Zhong</surname><given-names>J.C.</given-names></name><name><surname>Turner</surname><given-names>A.J.</given-names></name><name><surname>Raizada</surname><given-names>M.K.</given-names></name><name><surname>Grant</surname><given-names>M.B.</given-names></name><name><surname>Oudit</surname><given-names>G.Y.</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2: SARS-CoV-2 receptor and regulator of the renin-angiotensin system: Celebrating the 20th anniversary of the discovery of ACE2</article-title><source>Circ. Res.</source><volume>126</volume><year>2020</year><fpage>1456</fpage><lpage>1474</lpage><pub-id pub-id-type="pmid">32264791</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Groves</surname><given-names>H.T.</given-names></name><name><surname>Cuthbertson</surname><given-names>L.</given-names></name><name><surname>James</surname><given-names>P.</given-names></name><name><surname>Moffatt</surname><given-names>M.F.</given-names></name><name><surname>Cox</surname><given-names>M.J.</given-names></name><name><surname>Tregoning</surname><given-names>J.S.</given-names></name></person-group><article-title>Respiratory Disease following Viral Lung Infection Alters the Murine Gut Microbiota</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><fpage>182</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">29483910</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Lv</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>F.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Luo</surname><given-names>R.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name></person-group><article-title>Alterations of the gut microbiota in patients with COVID-19 or H1N1 Influenza</article-title><source>Clin. Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1093/cid/ciaa709</pub-id><comment>Published online June 4, 2020</comment></element-citation></ref><ref id="bib20"><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Guan</surname><given-names>W.J.</given-names></name><name><surname>Ni</surname><given-names>Z.Y.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>W.H.</given-names></name><name><surname>Ou</surname><given-names>C.Q.</given-names></name><name><surname>He</surname><given-names>J.X.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Shan</surname><given-names>H.</given-names></name><name><surname>Lei</surname><given-names>C.L.</given-names></name><name><surname>Hui</surname><given-names>D.S.C.</given-names></name><collab>China Medical Treatment Expert Group for Covid-19</collab></person-group><article-title>Clinical characteristics of Coronavirus Disease 2019 in China</article-title><source>N.&#x000a0;Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>1708</fpage><lpage>1720</lpage><pub-id pub-id-type="pmid">32109013</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Hamming</surname><given-names>I.</given-names></name><name><surname>Timens</surname><given-names>W.</given-names></name><name><surname>Bulthuis</surname><given-names>M.L.C.</given-names></name><name><surname>Lely</surname><given-names>A.T.</given-names></name><name><surname>Navis</surname><given-names>G.</given-names></name><name><surname>van Goor</surname><given-names>H.</given-names></name></person-group><article-title>Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis</article-title><source>J.&#x000a0;Pathol.</source><volume>203</volume><year>2004</year><fpage>631</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">15141377</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Hashimoto</surname><given-names>T.</given-names></name><name><surname>Perlot</surname><given-names>T.</given-names></name><name><surname>Rehman</surname><given-names>A.</given-names></name><name><surname>Trichereau</surname><given-names>J.</given-names></name><name><surname>Ishiguro</surname><given-names>H.</given-names></name><name><surname>Paolino</surname><given-names>M.</given-names></name><name><surname>Sigl</surname><given-names>V.</given-names></name><name><surname>Hanada</surname><given-names>T.</given-names></name><name><surname>Hanada</surname><given-names>R.</given-names></name><name><surname>Lipinski</surname><given-names>S.</given-names></name></person-group><article-title>ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation</article-title><source>Nature</source><volume>487</volume><year>2012</year><fpage>477</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">22837003</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Helms</surname><given-names>J.</given-names></name><name><surname>Kremer</surname><given-names>S.</given-names></name><name><surname>Merdji</surname><given-names>H.</given-names></name><name><surname>Clere-Jehl</surname><given-names>R.</given-names></name><name><surname>Schenck</surname><given-names>M.</given-names></name><name><surname>Kummerlen</surname><given-names>C.</given-names></name><name><surname>Collange</surname><given-names>O.</given-names></name><name><surname>Boulay</surname><given-names>C.</given-names></name><name><surname>Fafi-Kremer</surname><given-names>S.</given-names></name><name><surname>Ohana</surname><given-names>M.</given-names></name></person-group><article-title>Neurologic features in Severe SARS-CoV-2 infection</article-title><source>N.&#x000a0;Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>2268</fpage><lpage>2270</lpage><pub-id pub-id-type="pmid">32294339</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M.</given-names></name><name><surname>Kleine-Weber</surname><given-names>H.</given-names></name><name><surname>Schroeder</surname><given-names>S.</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N.</given-names></name><name><surname>Herrler</surname><given-names>T.</given-names></name><name><surname>Erichsen</surname><given-names>S.</given-names></name><name><surname>Schiergens</surname><given-names>T.S.</given-names></name><name><surname>Herrler</surname><given-names>G.</given-names></name><name><surname>Wu</surname><given-names>N.H.</given-names></name><name><surname>Nitsche</surname><given-names>A.</given-names></name></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>271</fpage><lpage>280.e8</lpage><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Honce</surname><given-names>R.</given-names></name><name><surname>Schultz-Cherry</surname><given-names>S.</given-names></name></person-group><article-title>Impact of obesity on Influenza A Virus pathogenesis, immune response, and evolution</article-title><source>Front. Immunol.</source><volume>10</volume><year>2019</year><fpage>1071</fpage><lpage>1084</lpage><pub-id pub-id-type="pmid">31134099</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Ren</surname><given-names>L.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Xu</surname><given-names>J.</given-names></name><name><surname>Gu</surname><given-names>X.</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>497</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Ichinohe</surname><given-names>T.</given-names></name><name><surname>Pang</surname><given-names>I.K.</given-names></name><name><surname>Kumamoto</surname><given-names>Y.</given-names></name><name><surname>Peaper</surname><given-names>D.R.</given-names></name><name><surname>Ho</surname><given-names>J.H.</given-names></name><name><surname>Murray</surname><given-names>T.S.</given-names></name><name><surname>Iwasaki</surname><given-names>A.</given-names></name></person-group><article-title>Microbiota regulates immune defense against respiratory tract influenza A virus infection</article-title><source>Proc. Natl. Acad. Sci. USA</source><volume>108</volume><year>2011</year><fpage>5354</fpage><lpage>5359</lpage><pub-id pub-id-type="pmid">21402903</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>X.</given-names></name><name><surname>Lian</surname><given-names>J.S.</given-names></name><name><surname>Hu</surname><given-names>J.H.</given-names></name><name><surname>Gao</surname><given-names>J.</given-names></name><name><surname>Zheng</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>Y.M.</given-names></name><name><surname>Hao</surname><given-names>S.R.</given-names></name><name><surname>Jia</surname><given-names>H.Y.</given-names></name><name><surname>Cai</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>X.L.</given-names></name></person-group><article-title>Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms</article-title><source>Gut</source><volume>69</volume><year>2020</year><fpage>1002</fpage><lpage>1009</lpage><pub-id pub-id-type="pmid">32213556</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Rigatto</surname><given-names>K.</given-names></name><name><surname>Gazzana</surname><given-names>M.B.</given-names></name><name><surname>Knorst</surname><given-names>M.M.</given-names></name><name><surname>Richards</surname><given-names>E.M.</given-names></name><name><surname>Pepine</surname><given-names>C.J.</given-names></name><name><surname>Raizada</surname><given-names>M.K.</given-names></name></person-group><article-title>Altered gut microbiome profile in patients with pulmonary arterial hypertension</article-title><source>Hypertension</source><volume>75</volume><year>2020</year><fpage>1063</fpage><lpage>1071</lpage><pub-id pub-id-type="pmid">32088998</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Kuba</surname><given-names>K.</given-names></name><name><surname>Imai</surname><given-names>Y.</given-names></name><name><surname>Rao</surname><given-names>S.</given-names></name><name><surname>Gao</surname><given-names>H.</given-names></name><name><surname>Guo</surname><given-names>F.</given-names></name><name><surname>Guan</surname><given-names>B.</given-names></name><name><surname>Huan</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Deng</surname><given-names>W.</given-names></name></person-group><article-title>A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury</article-title><source>Nat. Med.</source><volume>11</volume><year>2005</year><fpage>875</fpage><lpage>879</lpage><pub-id pub-id-type="pmid">16007097</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Lamers</surname><given-names>M.M.</given-names></name><name><surname>Beumer</surname><given-names>J.</given-names></name><name><surname>van der Vaart</surname><given-names>J.</given-names></name><name><surname>Knoops</surname><given-names>K.</given-names></name><name><surname>Puschhof</surname><given-names>J.</given-names></name><name><surname>Breugem</surname><given-names>T.I.</given-names></name><name><surname>Ravelli</surname><given-names>R.B.G.</given-names></name><name><surname>van Schayck</surname><given-names>J.P.</given-names></name><name><surname>Mykytyn</surname><given-names>A.Z.</given-names></name><name><surname>Duimel</surname><given-names>H.Q.</given-names></name></person-group><article-title>SARS-CoV-2 productively infects human gut enterocytes</article-title><source>Science</source><year>2020</year><pub-id pub-id-type="doi">10.1126/science.abc1669</pub-id><comment>Published online May 1, 2020</comment></element-citation></ref><ref id="bib32"><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Lavelle</surname><given-names>A.</given-names></name><name><surname>Sokol</surname><given-names>H.</given-names></name></person-group><article-title>Gut microbiota-derived metabolites as key actors in inflammatory bowel disease</article-title><source>Nat. Rev. Gastroenterol. Hepatol.</source><volume>17</volume><year>2020</year><fpage>223</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">32076145</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>W.</given-names></name><name><surname>Feng</surname><given-names>Z.</given-names></name><name><surname>Rao</surname><given-names>S.</given-names></name><name><surname>Xiao</surname><given-names>C.</given-names></name><name><surname>Xue</surname><given-names>X.</given-names></name><name><surname>Lin</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Qi</surname><given-names>W.</given-names></name></person-group><article-title>Diarrhoea may be underestimated: a missing link in 2019 novel coronavirus</article-title><source>Gut</source><volume>69</volume><year>2020</year><fpage>1141</fpage><lpage>1143</lpage><pub-id pub-id-type="pmid">32102928</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>L.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Huang</surname><given-names>S.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Fang</surname><given-names>Z.</given-names></name><name><surname>Gu</surname><given-names>Z.</given-names></name><name><surname>Gao</surname><given-names>L.</given-names></name><name><surname>Shi</surname><given-names>H.</given-names></name><name><surname>Mai</surname><given-names>L.</given-names></name></person-group><article-title>Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection</article-title><source>Gut</source><volume>69</volume><year>2020</year><fpage>997</fpage><lpage>1001</lpage><pub-id pub-id-type="pmid">32241899</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Lukassen</surname><given-names>S.</given-names></name><name><surname>Chua</surname><given-names>R.L.</given-names></name><name><surname>Trefzer</surname><given-names>T.</given-names></name><name><surname>Kahn</surname><given-names>N.C.</given-names></name><name><surname>Schneider</surname><given-names>M.A.</given-names></name><name><surname>Muley</surname><given-names>T.</given-names></name><name><surname>Winter</surname><given-names>H.</given-names></name><name><surname>Meister</surname><given-names>M.</given-names></name><name><surname>Veith</surname><given-names>C.</given-names></name><name><surname>Boots</surname><given-names>A.W.</given-names></name></person-group><article-title>SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells</article-title><source>EMBO J.</source><volume>39</volume><year>2020</year><fpage>e105114</fpage><pub-id pub-id-type="pmid">32246845</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>R.</given-names></name><name><surname>Qiu</surname><given-names>Y.</given-names></name><name><surname>He</surname><given-names>J.S.</given-names></name><name><surname>Tan</surname><given-names>J.Y.</given-names></name><name><surname>Li</surname><given-names>X.H.</given-names></name><name><surname>Liang</surname><given-names>J.</given-names></name><name><surname>Shen</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>L.R.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><name><surname>Iacucci</surname><given-names>M.</given-names></name></person-group><article-title>Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis</article-title><source>Lancet Gastroenterol. Hepatol.</source><volume>5</volume><year>2020</year><fpage>667</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">32405603</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>S.</given-names></name><name><surname>Nagata</surname><given-names>N.</given-names></name><name><surname>Shirato</surname><given-names>K.</given-names></name><name><surname>Kawase</surname><given-names>M.</given-names></name><name><surname>Takeda</surname><given-names>M.</given-names></name><name><surname>Taguchi</surname><given-names>F.</given-names></name></person-group><article-title>Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2</article-title><source>J.&#x000a0;Virol.</source><volume>84</volume><year>2010</year><fpage>12658</fpage><lpage>12664</lpage><pub-id pub-id-type="pmid">20926566</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>McCullers</surname><given-names>J.A.</given-names></name></person-group><article-title>The co-pathogenesis of influenza viruses with bacteria in the lung</article-title><source>Nat. Rev. Microbiol.</source><volume>12</volume><year>2014</year><fpage>252</fpage><lpage>262</lpage><pub-id pub-id-type="pmid">24590244</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Nobel</surname><given-names>Y.R.</given-names></name><name><surname>Phipps</surname><given-names>M.</given-names></name><name><surname>Zucker</surname><given-names>J.</given-names></name><name><surname>Lebwohl</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>T.C.</given-names></name><name><surname>Sobieszczyk</surname><given-names>M.E.</given-names></name><name><surname>Freedberg</surname><given-names>D.E.</given-names></name></person-group><article-title>Gastrointestinal symptoms and coronavirus disease 2019: a case-control study from the United States</article-title><source>Gastroenterology</source><year>2020</year><pub-id pub-id-type="doi">10.1053/j.gastro.2020.04.017</pub-id><comment>Published online April 12, 2020</comment></element-citation></ref><ref id="bib40"><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>L.</given-names></name><name><surname>Mu</surname><given-names>M.</given-names></name><name><surname>Yang</surname><given-names>P.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>R.</given-names></name><name><surname>Yan</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>P.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name></person-group><article-title>Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: A descriptive, cross-Sectional, multicenter study</article-title><source>Am. J. Gastroenterol.</source><volume>115</volume><year>2020</year><fpage>766</fpage><lpage>773</lpage><pub-id pub-id-type="pmid">32287140</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Paniz-Mondolfi</surname><given-names>A.</given-names></name><name><surname>Bryce</surname><given-names>C.</given-names></name><name><surname>Grimes</surname><given-names>Z.</given-names></name><name><surname>Gordon</surname><given-names>R.E.</given-names></name><name><surname>Reidy</surname><given-names>J.</given-names></name><name><surname>Lednicky</surname><given-names>J.</given-names></name><name><surname>Sordillo</surname><given-names>E.M.</given-names></name><name><surname>Fowkes</surname><given-names>M.</given-names></name></person-group><article-title>Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)</article-title><source>J.&#x000a0;Med. Virol.</source><volume>92</volume><year>2020</year><fpage>699</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">32314810</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Qin</surname><given-names>N.</given-names></name><name><surname>Zheng</surname><given-names>B.</given-names></name><name><surname>Yao</surname><given-names>J.</given-names></name><name><surname>Guo</surname><given-names>L.</given-names></name><name><surname>Zuo</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>L.</given-names></name><name><surname>Guo</surname><given-names>J.</given-names></name><name><surname>Ni</surname><given-names>S.</given-names></name></person-group><article-title>Influence of H7N9 virus infection and associated treatment on human gut microbiota</article-title><source>Sci. Rep.</source><volume>5</volume><year>2015</year><fpage>14771</fpage><lpage>14784</lpage><pub-id pub-id-type="pmid">26490635</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Ranjbar</surname><given-names>R.</given-names></name><name><surname>Shafiee</surname><given-names>M.</given-names></name><name><surname>Hesari</surname><given-names>A.</given-names></name><name><surname>Ferns</surname><given-names>G.A.</given-names></name><name><surname>Ghasemi</surname><given-names>F.</given-names></name><name><surname>Avan</surname><given-names>A.</given-names></name></person-group><article-title>The potential therapeutic use of renin-angiotensin system inhibitors in the treatment of inflammatory diseases</article-title><source>J.&#x000a0;Cell. Physiol.</source><volume>234</volume><year>2019</year><fpage>2277</fpage><lpage>2295</lpage><pub-id pub-id-type="pmid">30191985</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Redd</surname><given-names>W.D.</given-names></name><name><surname>Zhou</surname><given-names>J.C.</given-names></name><name><surname>Hathorn</surname><given-names>K.E.</given-names></name><name><surname>McCarty</surname><given-names>T.R.</given-names></name><name><surname>Bazarbashi</surname><given-names>A.N.</given-names></name><name><surname>Thompson</surname><given-names>C.C.</given-names></name><name><surname>Shen</surname><given-names>L.</given-names></name><name><surname>Chan</surname><given-names>W.W.</given-names></name></person-group><article-title>Prevalence and characteristics of gastrointestinal symptoms in patients with SARS-CoV-2 infection in the United States: A multicenter cohort study</article-title><source>Gastroenterology</source><year>2020</year><pub-id pub-id-type="doi">10.1053/j.gastro.2020.04.045</pub-id><comment>Published online April 22, 2020</comment></element-citation></ref><ref id="bib45"><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Santisteban</surname><given-names>M.M.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Pepine</surname><given-names>C.J.</given-names></name><name><surname>Raizada</surname><given-names>M.K.</given-names></name></person-group><article-title>Brain-gut-bone marrow axis: Implications for hypertension and related therapeutics</article-title><source>Circ. Res.</source><volume>118</volume><year>2016</year><fpage>1327</fpage><lpage>1336</lpage><pub-id pub-id-type="pmid">27081113</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Sencio</surname><given-names>V.</given-names></name><name><surname>Barthelemy</surname><given-names>A.</given-names></name><name><surname>Tavares</surname><given-names>L.P.</given-names></name><name><surname>Machado</surname><given-names>M.G.</given-names></name><name><surname>Soulard</surname><given-names>D.</given-names></name><name><surname>Cuinat</surname><given-names>C.</given-names></name><name><surname>Queiroz-Junior</surname><given-names>C.M.</given-names></name><name><surname>Noordine</surname><given-names>M.L.</given-names></name><name><surname>Salom&#x000e9;-Desnoulez</surname><given-names>S.</given-names></name><name><surname>Deryuter</surname><given-names>L.</given-names></name></person-group><article-title>Gut dysbiosis during influenza contributes to pulmonary pneumococcal superinfection through altered short-chain fatty acid production</article-title><source>Cell Rep.</source><volume>30</volume><year>2020</year><fpage>2934</fpage><lpage>2947.e6</lpage><pub-id pub-id-type="pmid">32130898</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>A.K.</given-names></name><name><surname>Gupta</surname><given-names>R.</given-names></name><name><surname>Ghosh</surname><given-names>A.</given-names></name><name><surname>Misra</surname><given-names>A.</given-names></name></person-group><article-title>Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations</article-title><source>Diabetes Metab. Syndr.</source><volume>14</volume><year>2020</year><fpage>303</fpage><lpage>310</lpage><pub-id pub-id-type="pmid">32298981</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Singhal</surname><given-names>R.</given-names></name><name><surname>Shah</surname><given-names>Y.M.</given-names></name></person-group><article-title>Oxygen battle in the gut: hypoxia and hypoxia-inducible factors in metabolic and inflammatory responses in the intestine</article-title><source>J.&#x000a0;Biol. Chem.</source><year>2020</year><pub-id pub-id-type="doi">10.1074/jbc.REV120.011188</pub-id><comment>Published online June 5, 2020</comment></element-citation></ref><ref id="bib49"><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Steed</surname><given-names>A.L.</given-names></name><name><surname>Christophi</surname><given-names>G.P.</given-names></name><name><surname>Kaiko</surname><given-names>G.E.</given-names></name><name><surname>Sun</surname><given-names>L.</given-names></name><name><surname>Goodwin</surname><given-names>V.M.</given-names></name><name><surname>Jain</surname><given-names>U.</given-names></name><name><surname>Esaulova</surname><given-names>E.</given-names></name><name><surname>Artyomov</surname><given-names>M.N.</given-names></name><name><surname>Morales</surname><given-names>D.J.</given-names></name><name><surname>Holtzman</surname><given-names>M.J.</given-names></name></person-group><article-title>The microbial metabolite desaminotyrosine protects from influenza through type I interferon</article-title><source>Science</source><volume>357</volume><year>2017</year><fpage>498</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">28774928</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Sultan</surname><given-names>S.</given-names></name><name><surname>Altayar</surname><given-names>O.</given-names></name><name><surname>Siddique</surname><given-names>S.M.</given-names></name><name><surname>Davitkov</surname><given-names>P.</given-names></name><name><surname>Feuerstein</surname><given-names>J.D.</given-names></name><name><surname>Lim</surname><given-names>J.K.</given-names></name><name><surname>Falck-Ytter</surname><given-names>Y.</given-names></name><name><surname>El-Serag</surname><given-names>H.B.</given-names></name><collab>American Gastroenterological Association</collab></person-group><article-title>AGA institute rapid review of the gastrointestinal and liver manifestations of COVID-19, meta-analysis of international data, and recommendations for the consultative management of patients with COVID-19</article-title><source>Gastroenterology</source><year>2020</year><pub-id pub-id-type="doi">10.1053/j.gastro.2020.05.001</pub-id><comment>Published online May 11, 2020</comment></element-citation></ref><ref id="bib51"><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>S.-H.</given-names></name><name><surname>Chen</surname><given-names>Q.</given-names></name><name><surname>Gu</surname><given-names>H.-J.</given-names></name><name><surname>Yang</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>Y.-X.</given-names></name><name><surname>Huang</surname><given-names>X.-Y.</given-names></name><name><surname>Liu</surname><given-names>S.-S.</given-names></name><name><surname>Zhang</surname><given-names>N.-N.</given-names></name><name><surname>Li</surname><given-names>X.-F.</given-names></name><name><surname>Xiong</surname><given-names>R.</given-names></name></person-group><article-title>A mouse model of SARS-CoV-2 infection and pathogenesis</article-title><source>Cell Host Microbe</source><year>2020</year><pub-id pub-id-type="doi">10.1016/j.chom.2020.05.020</pub-id><comment>Published online May 27, 2020</comment></element-citation></ref><ref id="bib52"><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Sungnak</surname><given-names>W.</given-names></name><name><surname>Huang</surname><given-names>N.</given-names></name><name><surname>B&#x000e9;cavin</surname><given-names>C.</given-names></name><name><surname>Berg</surname><given-names>M.</given-names></name><name><surname>Queen</surname><given-names>R.</given-names></name><name><surname>Litvinukova</surname><given-names>M.</given-names></name><name><surname>Talavera-L&#x000f3;pez</surname><given-names>C.</given-names></name><name><surname>Maatz</surname><given-names>H.</given-names></name><name><surname>Reichart</surname><given-names>D.</given-names></name><name><surname>Sampaziotis</surname><given-names>F.</given-names></name><collab>HCA Lung Biological Network</collab></person-group><article-title>SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes</article-title><source>Nat. Med.</source><volume>26</volume><year>2020</year><fpage>681</fpage><lpage>687</lpage><pub-id pub-id-type="pmid">32327758</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Trompette</surname><given-names>A.</given-names></name><name><surname>Gollwitzer</surname><given-names>E.S.</given-names></name><name><surname>Pattaroni</surname><given-names>C.</given-names></name><name><surname>Lopez-Mejia</surname><given-names>I.C.</given-names></name><name><surname>Riva</surname><given-names>E.</given-names></name><name><surname>Pernot</surname><given-names>J.</given-names></name><name><surname>Ubags</surname><given-names>N.</given-names></name><name><surname>Fajas</surname><given-names>L.</given-names></name><name><surname>Nicod</surname><given-names>L.P.</given-names></name><name><surname>Marsland</surname><given-names>B.J.</given-names></name></person-group><article-title>Dietary fiber confers protection against flu by shaping Ly6c<sup>&#x02212;</sup> patrolling monocyte hematopoiesis and CD8<sup>+</sup> T&#x000a0;cell metabolism</article-title><source>Immunity</source><volume>48</volume><year>2018</year><fpage>992</fpage><lpage>1005.e8</lpage><pub-id pub-id-type="pmid">29768180</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Wei</surname><given-names>H.</given-names></name><name><surname>Lian</surname><given-names>Z.-X.</given-names></name><name><surname>Sun</surname><given-names>R.</given-names></name><name><surname>Tian</surname><given-names>Z.</given-names></name></person-group><article-title>Respiratory influenza virus infection induces intestinal immune injury via microbiota-mediated Th17 cell-dependent inflammation</article-title><source>J.&#x000a0;Exp. Med.</source><volume>211</volume><year>2014</year><fpage>2397</fpage><lpage>2410</lpage><pub-id pub-id-type="pmid">25366965</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>C.</given-names></name><name><surname>Horby</surname><given-names>P.W.</given-names></name><name><surname>Hayden</surname><given-names>F.G.</given-names></name><name><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>A novel coronavirus outbreak of global health concern</article-title><source>Lancet</source><volume>395</volume><year>2020</year><fpage>470</fpage><lpage>473</lpage><pub-id pub-id-type="pmid">31986257</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q.</given-names></name><name><surname>Zhang</surname><given-names>Y.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Niu</surname><given-names>S.</given-names></name><name><surname>Song</surname><given-names>C.</given-names></name><name><surname>Zhang</surname><given-names>Z.</given-names></name><name><surname>Lu</surname><given-names>G.</given-names></name><name><surname>Qiao</surname><given-names>C.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name></person-group><article-title>Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>894</fpage><lpage>904.e9</lpage><pub-id pub-id-type="pmid">32275855</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Hu</surname><given-names>C.</given-names></name><name><surname>Zhu</surname><given-names>F.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>B.</given-names></name><name><surname>Xiang</surname><given-names>H.</given-names></name><name><surname>Cheng</surname><given-names>Z.</given-names></name><name><surname>Xiong</surname><given-names>Y.</given-names></name></person-group><article-title>Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China</article-title><source>JAMA</source><volume>323</volume><year>2020</year><fpage>1061</fpage><lpage>1069</lpage></element-citation></ref><ref id="bib58"><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Z.</given-names></name><name><surname>McGoogan</surname><given-names>J.M.</given-names></name></person-group><article-title>Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72&#x000a0;314 cases from the Chinese center for disease control and prevention</article-title><source>JAMA</source><year>2020</year><pub-id pub-id-type="doi">10.1001/jama.2020.2648</pub-id><comment>Published online February 24, 2020</comment></element-citation></ref><ref id="bib59"><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>F.</given-names></name><name><surname>Tang</surname><given-names>M.</given-names></name><name><surname>Zheng</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Shan</surname><given-names>H.</given-names></name></person-group><article-title>Evidence for gastrointestinal infection of SARS-CoV-2</article-title><source>Gastroenterology</source><volume>158</volume><year>2020</year><fpage>1831</fpage><lpage>1833.e3</lpage><pub-id pub-id-type="pmid">32142773</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>F.</given-names></name><name><surname>Sun</surname><given-names>J.</given-names></name><name><surname>Xu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Huand</surname><given-names>X.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Zhoa</surname><given-names>J.</given-names></name><name><surname>Huang</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>J.</given-names></name></person-group><article-title>Infectious SARS-CoV-2 in feces of patient with Severe COVID-19</article-title><source>Emerg. Infect. Dis.</source><volume>26</volume><year>2020</year><pub-id pub-id-type="doi">10.3201/eid2608.200681</pub-id><comment>Published online May 18, 2020</comment></element-citation></ref><ref id="bib61"><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Yildiz</surname><given-names>S.</given-names></name><name><surname>Mazel-Sanchez</surname><given-names>B.</given-names></name><name><surname>Kandasamy</surname><given-names>M.</given-names></name><name><surname>Manicassamy</surname><given-names>B.</given-names></name><name><surname>Schmolke</surname><given-names>M.</given-names></name></person-group><article-title>Influenza A virus infection impacts systemic microbiota dynamics and causes quantitative enteric dysbiosis</article-title><source>Microbiome</source><volume>6</volume><year>2018</year><fpage>9</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">29321057</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>L.</given-names></name><name><surname>Tong</surname><given-names>Y.</given-names></name><name><surname>Shen</surname><given-names>G.</given-names></name><name><surname>Fu</surname><given-names>A.</given-names></name><name><surname>Lai</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>X.</given-names></name><name><surname>Yan</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Pan</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>Z.</given-names></name></person-group><article-title>Immunodepletion with hypoxemia: A potential high risk subtype of coronavirus disease 2019</article-title><source>medRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.03.03.20030650</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Zang</surname><given-names>R.</given-names></name><name><surname>Gomez Castro</surname><given-names>M.F.</given-names></name><name><surname>McCune</surname><given-names>B.T.</given-names></name><name><surname>Zeng</surname><given-names>Q.</given-names></name><name><surname>Rothlauf</surname><given-names>P.W.</given-names></name><name><surname>Sonnek</surname><given-names>N.M.</given-names></name><name><surname>Liu</surname><given-names>Z.</given-names></name><name><surname>Brulois</surname><given-names>K.F.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Greenberg</surname><given-names>H.B.</given-names></name></person-group><article-title>TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes</article-title><source>Sci. Immunol.</source><volume>5</volume><year>2020</year><fpage>eabc3582</fpage><pub-id pub-id-type="pmid">32404436</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Du</surname><given-names>R.H.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Zheng</surname><given-names>X.S.</given-names></name><name><surname>Yang</surname><given-names>X.L.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Wang</surname><given-names>Y.Y.</given-names></name><name><surname>Xiao</surname><given-names>G.F.</given-names></name><name><surname>Yan</surname><given-names>B.</given-names></name><name><surname>Shi</surname><given-names>Z.L.</given-names></name><name><surname>Zhou</surname><given-names>P.</given-names></name></person-group><article-title>Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes</article-title><source>Emerg. Microbes Infect.</source><volume>9</volume><year>2020</year><fpage>386</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">32065057</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Y.</given-names></name><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Zhou</surname><given-names>Y.</given-names></name><name><surname>Ma</surname><given-names>Y.</given-names></name><name><surname>Zuo</surname><given-names>W.</given-names></name></person-group><article-title>Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov</article-title><source>bioRxiv</source><year>2020</year><pub-id pub-id-type="doi">10.1101/2020.01.26.919985</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal" id="sref66"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>X.L.</given-names></name><name><surname>Wang</surname><given-names>X.G.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Si</surname><given-names>H.R.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Huang</surname><given-names>C.L.</given-names></name></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><volume>579</volume><year>2020</year><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal" id="sref67"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Z.</given-names></name><name><surname>Zhao</surname><given-names>N.</given-names></name><name><surname>Shu</surname><given-names>Y.</given-names></name><name><surname>Han</surname><given-names>S.</given-names></name><name><surname>Chen</surname><given-names>B.</given-names></name><name><surname>Shu</surname><given-names>X.</given-names></name></person-group><article-title>Effect of gastrointestinal symptoms in patients with COVID-19</article-title><source>Gastroenterology</source><volume>158</volume><year>2020</year><fpage>2294</fpage><lpage>2297</lpage><pub-id pub-id-type="pmid">32199880</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal" id="sref68"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>C.</given-names></name><name><surname>Liu</surname><given-names>X.</given-names></name><name><surname>Chiu</surname><given-names>M.C.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Wei</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>A.</given-names></name><name><surname>Zhang</surname><given-names>A.J.</given-names></name><name><surname>Chu</surname><given-names>H.</given-names></name></person-group><article-title>Infection of bat and human intestinal organoids by SARS-CoV-2</article-title><source>Nat. Med.</source><volume>2020</volume><year>2020</year><fpage>13</fpage></element-citation></ref><ref id="bib69"><element-citation publication-type="journal" id="sref69"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>N.</given-names></name><name><surname>Zhang</surname><given-names>D.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Yang</surname><given-names>B.</given-names></name><name><surname>Song</surname><given-names>J.</given-names></name><name><surname>Zhao</surname><given-names>X.</given-names></name><name><surname>Huang</surname><given-names>B.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Lu</surname><given-names>R.</given-names></name><collab>China Novel Coronavirus Investigating and Research Team</collab></person-group><article-title>A Novel Coronavirus from Patients with Pneumonia in China, 2019</article-title><source>N.&#x000a0;Engl. J. Med.</source><volume>382</volume><year>2020</year><fpage>727</fpage><lpage>733</lpage><pub-id pub-id-type="pmid">31978945</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal" id="sref70"><person-group person-group-type="author"><name><surname>Zuo</surname><given-names>T.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Lui</surname><given-names>G.C.Y.</given-names></name><name><surname>Yeoh</surname><given-names>Y.K.</given-names></name><name><surname>Li</surname><given-names>A.Y.L.</given-names></name><name><surname>Zhan</surname><given-names>H.</given-names></name><name><surname>Wan</surname><given-names>Y.</given-names></name><name><surname>Chung</surname><given-names>A.</given-names></name><name><surname>Cheung</surname><given-names>C.P.</given-names></name><name><surname>Chen</surname><given-names>N.</given-names></name></person-group><article-title>Alterations in gut microbiota of patients with COVID-19 during time of hospitalization</article-title><source>Gastroenterology</source><year>2020</year><pub-id pub-id-type="doi">10.1053/j.gastro.2020.05.048</pub-id><comment>Published online May 19, 2020</comment></element-citation></ref></ref-list><ack id="ack0010"><title>Acknowledgments</title><p>We acknowledge support from our funding agencies <funding-source id="gs1"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100001677</institution-id><institution>Institut National de la Sant&#x000e9; et de la Recherche M&#x000e9;dicale</institution></institution-wrap></funding-source>, the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004794</institution-id><institution>Centre National de la Recherche Scientifique</institution></institution-wrap></funding-source> (CNRS), the <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/100015872</institution-id><institution>University of Lille</institution></institution-wrap></funding-source>, the <funding-source id="gs4"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100013340</institution-id><institution>Pasteur Institute of Lille</institution></institution-wrap></funding-source>, the <funding-source id="gs5">R&#x000e9;gion des Hauts-de-France</funding-source>, and <funding-source id="gs6">l&#x02019;Agence Nationale de la Recherche</funding-source> (AAP g&#x000e9;n&#x000e9;rique 2017, ANR-17-CE15-0020-01, ACROBAT) (to F.T.). F.T. received salary support from <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100004794</institution-id><institution>CNRS</institution></institution-wrap></funding-source>, and H.S. received salary support from <funding-source id="gs8">Sorbonne Universit&#x000e9;</funding-source> and <funding-source id="gs9">Saint Antoine Hospital</funding-source>. We thank Corinne Grangette and Isabelle Wolowczuk (Centre d&#x02019;Infection et d&#x02019;Immunit&#x000e9; de Lille) for critical comments on the manuscript.</p></ack></back></article>